Literature DB >> 19161874

Postnatal corticosteroids for bronchopulmonary dysplasia.

Alan H Jobe1.   

Abstract

Corticosteroids are used to improve lung function in infants who are progressing toward bronchopulmonary dysplasia. Corticosteroids facilitate extubation, but there is conflicting information about adverse effects on the developing brain. An approach to minimizing risk is to use low-dose, short-duration treatments in the highest risk ventilator-dependent patients. Questions remain about which corticosteroid is the safest and how to dose that corticosteroid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161874      PMCID: PMC2663397          DOI: 10.1016/j.clp.2008.09.016

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  52 in total

Review 1.  Inflammation and bronchopulmonary dysplasia.

Authors:  Christian P Speer
Journal:  Semin Neonatol       Date:  2003-02

Review 2.  Adrenocortical function and dysfunction in the fetus and neonate.

Authors:  Kristi L Watterberg
Journal:  Semin Neonatol       Date:  2004-02

3.  Relationship between histologic chorioamnionitis and early inflammatory variables in blood, tracheal aspirates, and endotracheal colonization in preterm infants.

Authors:  Jozef De Dooy; Cecile Colpaert; Annemie Schuerwegh; Chris Bridts; Marc Van Der Planken; Margaretha Ieven; Luc De Clerck; Wim Stevens; Ludo Mahieu
Journal:  Pediatr Res       Date:  2003-04-02       Impact factor: 3.756

4.  Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes.

Authors:  Elizabeth J Short; Nancy K Klein; Barbara A Lewis; Sarah Fulton; Sheri Eisengart; Carolyn Kercsmar; Jill Baley; Lynn T Singer
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

5.  Reduced nephron number in adult sheep, hypertensive as a result of prenatal glucocorticoid treatment.

Authors:  E M Wintour; K M Moritz; K Johnson; S Ricardo; C S Samuel; M Dodic
Journal:  J Physiol       Date:  2003-05-02       Impact factor: 5.182

Review 6.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.

Authors:  H L Halliday; R A Ehrenkranz; L W Doyle
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.

Authors:  K L Watterberg; L M Demers; S M Scott; S Murphy
Journal:  Pediatrics       Date:  1996-02       Impact factor: 7.124

8.  Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity.

Authors:  Tsu F Yeh; Yuh J Lin; Hung C Lin; Chao C Huang; Wu S Hsieh; Chyi H Lin; Cheng H Tsai
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

Review 9.  Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants.

Authors:  S S Shah; A Ohlsson; H Halliday; V S Shah
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 10.  The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs.

Authors:  K J Barrington
Journal:  BMC Pediatr       Date:  2001-02-27       Impact factor: 2.125

View more
  14 in total

1.  Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant.

Authors:  Hong Zhang; Yi E Wang; Charles R Neal; Yi Y Zuo
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

Review 2.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

3.  Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant a a carrier.

Authors:  Yi E Wang; Hong Zhang; Qihui Fan; Charles R Neal; Yi Y Zuo
Journal:  Soft Matter       Date:  2011-11-01       Impact factor: 3.679

4.  Association of time of first corticosteroid treatment with bronchopulmonary dysplasia in preterm infants.

Authors:  Alain Cuna; Joanne M Lagatta; Rashmin C Savani; Shilpa Vyas-Read; William A Engle; Rebecca S Rose; Robert DiGeronimo; J Wells Logan; Michel Mikhael; Girija Natarajan; William E Truog; Matthew Kielt; Karna Murthy; Isabella Zaniletti; Tamorah R Lewis
Journal:  Pediatr Pulmonol       Date:  2021-08-11

5.  Lithium protects against glucocorticoid induced neural progenitor cell apoptosis in the developing cerebellum.

Authors:  Omar Cabrera; Joseph Dougherty; Sukrit Singh; Brant S Swiney; Nuri B Farber; Kevin K Noguchi
Journal:  Brain Res       Date:  2013-12-19       Impact factor: 3.252

Review 6.  Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia.

Authors:  Zeyar T Htun; Elizabeth V Schulz; Riddhi K Desai; Jaime L Marasch; Christopher C McPherson; Lucy D Mastrandrea; Alan H Jobe; Rita M Ryan
Journal:  J Perinatol       Date:  2021-05-19       Impact factor: 2.521

7.  Perinatal determinants of neonatal hair glucocorticoid concentrations.

Authors:  David Q Stoye; Gemma Sullivan; Paola Galdi; Clemens Kirschbaum; Gillian J Lamb; Gill S Black; Margaret J Evans; James P Boardman; Rebecca M Reynolds
Journal:  Psychoneuroendocrinology       Date:  2021-04-10       Impact factor: 4.905

Review 8.  Bronchopulmonary dysplasia early changes leading to long-term consequences.

Authors:  Anne Hilgendorff; Michael A O'Reilly
Journal:  Front Med (Lausanne)       Date:  2015-02-12

9.  Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

Authors:  Viraraghavan Vadakkencherry Ramaswamy; Tapas Bandyopadhyay; Debasish Nanda; Prathik Bandiya; Javed Ahmed; Anip Garg; Charles C Roehr; Sushma Nangia
Journal:  JAMA Pediatr       Date:  2021-06-07       Impact factor: 16.193

10.  Antioxidant and anti-inflammatory effects of Astragalus polysaccharide on EA.hy926 cells.

Authors:  Wei Min Huang; Yong Qi Liang; Li Jun Tang; Yue Ding; Xiao Hong Wang
Journal:  Exp Ther Med       Date:  2013-04-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.